INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 279 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,843,893 | +6.2% | 279,693 | +36.9% | 0.05% | +10.4% |
| Q2 2023 | $8,330,375 | +9.4% | 204,276 | 0.0% | 0.05% | +6.7% |
| Q1 2023 | $7,613,367 | +6.8% | 204,276 | 0.0% | 0.04% | +7.1% |
| Q4 2022 | $7,127,190 | -37.7% | 204,276 | 0.0% | 0.04% | -38.2% |
| Q3 2022 | $11,431,285 | +8.1% | 204,276 | 0.0% | 0.07% | +17.2% |
| Q2 2022 | $10,573,326 | -28.8% | 204,276 | 0.0% | 0.06% | -7.9% |
| Q1 2022 | $14,844,737 | -38.5% | 204,276 | 0.0% | 0.06% | -27.6% |
| Q4 2021 | $24,154,000 | -70.1% | 204,276 | -66.1% | 0.09% | -69.1% |
| Q3 2021 | $80,737,000 | -36.9% | 601,839 | -23.9% | 0.28% | -34.1% |
| Q2 2021 | $127,994,000 | +101.7% | 790,527 | 0.0% | 0.43% | +71.9% |
| Q1 2021 | $63,444,000 | +47.5% | 790,527 | 0.0% | 0.25% | +34.6% |
| Q4 2020 | $43,005,000 | +173.6% | 790,527 | 0.0% | 0.18% | +131.2% |
| Q3 2020 | $15,716,000 | -5.4% | 790,527 | 0.0% | 0.08% | -19.2% |
| Q2 2020 | $16,617,000 | +71.9% | 790,527 | 0.0% | 0.10% | +39.4% |
| Q1 2020 | $9,668,000 | -16.6% | 790,527 | 0.0% | 0.07% | -6.6% |
| Q4 2019 | $11,597,000 | +9.9% | 790,527 | 0.0% | 0.08% | -1.3% |
| Q3 2019 | $10,554,000 | -18.4% | 790,527 | 0.0% | 0.08% | -16.3% |
| Q2 2019 | $12,941,000 | -4.2% | 790,527 | 0.0% | 0.09% | -1.1% |
| Q1 2019 | $13,502,000 | +25.1% | 790,527 | 0.0% | 0.09% | +25.7% |
| Q4 2018 | $10,791,000 | -52.3% | 790,527 | 0.0% | 0.07% | -43.9% |
| Q3 2018 | $22,625,000 | +4.6% | 790,527 | 0.0% | 0.13% | +15.8% |
| Q2 2018 | $21,629,000 | +29.7% | 790,527 | 0.0% | 0.11% | +25.3% |
| Q1 2018 | $16,672,000 | +9.7% | 790,527 | 0.0% | 0.09% | -2.2% |
| Q4 2017 | $15,194,000 | -22.7% | 790,527 | 0.0% | 0.09% | -18.4% |
| Q3 2017 | $19,645,000 | +55.3% | 790,527 | 0.0% | 0.11% | +39.0% |
| Q2 2017 | $12,648,000 | +13.5% | 790,527 | 0.0% | 0.08% | -1.2% |
| Q1 2017 | $11,139,000 | +7.5% | 790,527 | 0.0% | 0.08% | 0.0% |
| Q4 2016 | $10,364,000 | -23.0% | 790,527 | 0.0% | 0.08% | -23.9% |
| Q3 2016 | $13,455,000 | -20.3% | 790,527 | 0.0% | 0.11% | -17.4% |
| Q2 2016 | $16,878,000 | – | 790,527 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |